x 

0 Activities
0 Activities
    • No Saved Activities

Animation

  2. Home
  3. Content Type
  4. Animation
  5. Specialty Area
  6. Pharmacist
Results 1 - 74 of 74
9362_hemophilia_263x149
Monograph: A New Era for Hemophilia Treatment: Common Goals, Unique Perspectives
9362_hemophilia_263x149
Symposium: A New Era for Hemophilia Treatment: Common Goals, Unique Perspectives
Am I Treating My Patients With Psoriatic Disease Effectively?
Unraveling Cancer Pain Dynamics Adaptive Learning Module: A REMS-Compliant CE Activity
9364-amyloidosis-263x149
Cleveland Clinic Tall Rounds: Post‐diagnostic Monitoring of Cardiac Amyloidosis
9362_hemophilia_263x149
Rapid Recap: A New Era for Hemophilia Treatment: Common Goals, Unique Perspectives
9364-amyloidosis-263x149
Cleveland Clinic Tall Rounds: Treating Confirmed ATTR
9341-weight-mgmt
Weight Management in Community Health: Bridging Systems and Care Coordination
9350_isth_micro3
Microlearning: Novel Approaches Under Investigation in Hemophilia
9350_isth_micro2
Microlearning: Neutralizing Antibodies in Hemophilia
9350_isth_micro1
Microlearning: Durability of Gene Therapy in Hemophilia
9299 mda enduring
Evolutions in the Management of DMD: Treatment Implications for the Present and Future
9278-isth-explore
Hemophilia Gene Therapy: Shared Decision Making - Clinical Companion Guide
9278-isth-explore
Risks and Benefits of Hemophilia Gene Therapy: An EXPLORE Learning Experience
9285-t1d
A Changing Conversation: Delaying T1D Onset
9364-amyloidosis-263x149
Contemporary Strategies: Diagnosing ATTR Amyloidosis
animation-263x149
Encouraging Shared Decision-Making with MS Patients
9252 schiz
Cognitive Impairment Associated With Schizophrenia
9235-0005_thumb
Recent Developments in Immune Therapies for Multiple Sclerosis
9235-mod4-263x149
The Connection Between Viruses and Other Factors Contributing to the Development of MS
No image set
Comorbidities and Selection of DMTs
No image set
Management of Breakthrough Disease Activity in MS
No image set
COVID-19 Associated ARDS
No image set
COVID-19 and Comorbid ILD
No image set
Minimizing Neurodegenerative Damage in Patients with MS
No image set
Recognizing Progressive Disease: A Challenge in the MS Clinic
No image set
DMT Treatment Review
No image set
IPF Animated Video Series: Micro-learning focusing on the soft skills
No image set
Palliative Care for mRCC
No image set
Salvage Therapies for Metastatic Renal Cell Carcinoma
No image set
Is There Still a Role For Cytoreductive Nephrectomy
No image set
Management of Rare RCC Histologies
No image set
Contemporary Topics in RCC: Tumor Board
No image set
End of Life in IPF
No image set
Comprehensive Care of the ILD Patient–Focus on Symptoms
No image set
Developing an Action Plan to Manage IPF
No image set
Diagnosis of Interstitial Lung Disease
No image set
Applying Principles of Pain Management
No image set
Patient Case: Osteoarthritis (OA) of the Knee
No image set
Patient Case: Lower Back Pain
9916-cme-icon
Personalized Medicine for Improving Asthma Care: An Animated Video Series
9916-0005-icon
Discussions with Patients to Optimize Asthma Control
9916-0004_treatment
Who Should be Targeted For Treatment With Biologic Therapy?
9916-0003_endotypes
Endotypes and Phenotypes in Asthma
9916-0002_moa3
Mechanisms of Action of Biologic Therapies for Severe Asthma
9916-0001_meds
Approved Medications for the Treatment of Severe Asthma
9907-0006_shared
Engage Your Patients in Shared Decision-Making
9907-0005_cardio
Is It IPF or Cardiovascular Disease?
9907-0004_ip
Interstitial Pneumonia with Autoimmune Features
9907-0003_pf-ild
How to Identify Progressive Fibrosing ILD
9907-0002_ctd
When Is It a Connective Tissue Disease?
9907-0001_guidelines
How to Use IPF Guidelines to Make a Diagnosis
hopa-icon8
Biosimilars: Applying the Science to Hematology/Oncology Practice
IL-rheum-case3
Considering Biosimilars in Patients Failing their Initial Biologic
IL-rheum-case2
When to Switch? Biologically Experienced Patients with Spondyloarthritis
IL-rheum-case1
Innovator or Biosimilar for a Patient with Rheumatoid Arthritis
IL-gastro-case3
Ulcerative Colitis: What Can You Expect When a Patient is Switched to a Biosimilar?
IL-gastro-case2
Biosimilars in Patients with Crohn’s Disease Failing an Initial Biologic
IL-gastro-case1
Innovator or Biosimilar for a Patient with Ulcerative Colitis?
IL-derm-case3
Switching Between Biologics: Is a Biosimilar an Option?
IL-derm-case2
When to Switch? Biologically Experienced Psoriasis Patients
IL-derm-case1
Innovator or Biosimilar for a Patient with Psoriasis
IL-fund-case4
Interchangeability and Pharmacy-Level Substitution
IL-fund-case3
FDA Criteria: Biosimilar Approval, Manufacturing, & Naming
IL-fund-case2
What is the Difference Between a Biosimilar and a Generic?
IL-fund-case1
What is a Biologic?
biosims-full
Sorting it Out: Biologics, Biosimilars, Small Molecule Drugs, and Generics
biosims-green5
Are You Ready to Use Biosimilars in Your Practice?
biosims-full3
Health Care Providers’ Perspectives on Biosimilars: Based in Fact or Not?
biosims-green3
Pharmacovigilance and Biosimilars: Any Special Considerations?
biosims-full5
Interchangeability and Biosimilars: What will this Mean for Clinical Practice?
biosims-green8
Can a Biosimilar be Used for the Same Indications Approved for the Reference Biologic?
biosims-full7
Biosimilars: As Safe and Effective as the Reference Product?
biosims-green
Drift and the Manufacturing of Biologics: What is it and Does it Matter?
biosims-full8
Biosimilars in Clinical Practice: Interchangeability and Extrapolation

Search